Healthcare

Meet your Healthcare Research team

Malin Corporation

New Chairman appointed

Liam Daniel has been appointed Chairman of Malin with immediate effect. He replaces Ian Curley, whose departure was flagged by Malin at its AGM in May. We view the appointment of Daniel,...

Mainstay Medical

Completes financing; operational runway extended to 2021

Mainstay has completed its equity and debt financing transactions, raising gross proceeds of €16.9m ($18.9m). The company now has sufficient capital to advance its two main strategic...

Malin Corporation

Kymab to receive up to $30m investment

LifeArc has made an initial $10m equity investment in Kymab and has committed to invest a further $20m. LifeArc is a UK medical research charity that has deep pockets after it...

UDG Healthcare plc

H1 19: strong cashflow, 5% EPS upgrades on M&A

UDG has delivered a strong H1 19 performance. We estimate that underlying operating profit rose 6% and FCF conversion was very strong at 77%, putting UDG on track to meet its...

UDG Healthcare plc

Positive start to 2019; Ashfield now trading at up to a c.50% relative discount

UDG Healthcare’s (UDG) Q1 2019 update suggests that trading across the group is in-line with expectations. Guidance should also underpin confidence in market EPS numbers for 2019 and...

Venn Life Sciences

Partnership announcement

Venn has announced a partnership with Carrick Therapeutics, an Ireland and UK based biotech company developing treatments for aggressive forms of cancer. It has built a network of...

Malin Corporation

Sharpening the strategic focus

Malin is sharpening its strategic focus. It has simplified its strategy to focus on four priority assets that hold considerable upside, and the leaner structure provides a longer...

Mainstay Medical

ReActiv8-B pivotal trial data transformational catalyst in Q4

Mainstay Medical is a specialist medical device company developing and commercialising ReActiv8, an innovative therapy for chronic lower back pain. Mainstay could be on the cusp of a...

UDG Healthcare plc

Ashfield: getting a bad rep! Deep dive into Communications and Advisory opportunities

For many investors, Ashfield (UDG Healthcare’s largest division) is still synonymous with ‘sales reps’. Although this view is now wide of the mark, we think it explains much of the recent...